Article
HIV-1 co-receptor usage and variable loop contact impacts V3 loop bnAb susceptibility
2019-03-05
Abstract excerpt
<h4>ABSTRACT</h4> In clinical trials, HIV-1 broadly neutralizing antibodies (bnAbs) effectively lower plasma viremia and delay virus reemergence after antiretroviral treatment is stopped among infected individuals that have undetectable virus levels. Presence of less neutralization susceptible strains prior to treatment, however, decreases the efficacy of these antibody-based treatments. The HIV-1 envelope glycop...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 48df8394-3319-54b5-ad2e-896515491136
- DOI
- 10.1101/568469
